Skip to content
Publicly Available Published by De Gruyter December 4, 2017

Short-term adverse effects of testosterone used for priming in prepubertal boys before growth hormone stimulation test

  • Andrea Albrecht , Theresa Penger , Michaela Marx , Karin Hirsch and Helmuth G. Dörr EMAIL logo



Despite the fact that priming with sex steroids in prepubertal children before growth hormone (GH) provocative tests is recommended, there is an ongoing controversial discussion about the appropriate age of the children, the drug used for priming, the dose and the period between priming and the GH test. Interestingly, there is no discussion on the safety of this procedure. To date, only little data have been available on the possible side effects of priming with testosterone.


We analyzed the outcome in 188 short-statured prepubertal boys who had been primed with testosterone enanthate (n=136: 50 mg; n=51: 125 mg, and accidentally one boy with 250 mg) 7 days prior to the GH test. Serum testosterone levels were measured on the day of the GH test in 99 boys.


Overall, only five boys developed adverse side effects. Two boys (dose 125 mg) showed severe low-flow priapism and had to undergo decompression of the corpora cavernosa. One boy suffered from self-limiting priapism and testicular pain (dose 50 mg). Two patients reported testicular pain (each dose 50 mg). The single patient with 250 mg testosterone did not show any adverse effects. The total side effect rate was 2.7%. The serum testosterone levels of the boys with side effects were not different from the testosterone levels of the boys without any side effects.


Parents and patients should be informed about the possible side effects of priming with testosterone such as priapism and testicular pain. However, the overall side effect rate is low. We found no correlation between the outcome and the testosterone dose used and/or the level of serum testosterone.


The recommendation of priming with sex steroids in children before growth hormone (GH) provocative tests has changed in the recent years. In 2000, there was no consensus on the use of priming [1], whereas, in 2016, the updated guidelines of the Pediatric Endocrine Society recommended priming with sex steroids [2]. The German Society for Paediatric Endocrinology and Diabetology had already recommended priming in 2008 [3]. However, there are still some controversies. The guidelines of the Pediatric Endocrine Society limited priming to prepubertal girls >10 years and to prepubertal boys >11 years, whereas in Germany the ages for priming are ≥8 years for prepubertal girls and ≥10 years for prepubertal boys. According to Lazar and Phillip from Israel, priming should not be routinely performed in every peripubertal child undergoing GH evaluation but considered only in adolescents with pubertal delay, i.e. girls >11.5–12 years and boys >13–13.5 years [4]. The guidelines of the Paediatric Endocrine Society suggested giving β-estradiol orally to both boys and girls on two evenings preceding the test. The use of intramuscular (i.m.) testosterone (50–100 mg of a depot formulation administered 1 week before the test) was suggested as an alternative option [2], whereas, according to the German guidelines, boys should be primed with i.m. testosterone (50 mg testosterone enanthate) 1 week prior to the GH test [3]. Moreover, a study from the UK showed differences not only in the testosterone dosages but also in the testosterone preparation and the time between priming and the GH test [5].

Interestingly, there has been no discussion on the safety of this procedure. To date, only little data have been available on the possible side effects of priming with testosterone. Thus, the aim of our study was to evaluate the outcome in prepubertal boys primed with i.m. testosterone before GH axis testing and to analyze whether the applied dose or the achieved serum testosterone level after priming could be related to side effects.

Patients and methods

We studied a cohort of 188 prepubertal short-statured boys (mean age±SD; 11.4±1.25 years) with suspected GH deficiency. All boys were ≥10 years old.

Priming was performed by i.m. injection of a depot testosterone formulation (testosterone enanthate 250 mg/mL) 7 days before the GH stimulation test. The testosterone injections were performed by a home pediatrician or a medical practitioner. Between 2009 and 2010, we used a testosterone dose of 125 mg (n=51), and since 2011, all boys have been primed with a dose of 50 mg testosterone (n=136). One boy accidentally received 250 mg testosterone. At the time of the GH test, serum testosterone levels were measured in a cohort of 99 boys, among them four boys with reported side effects. Testosterone was measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in our laboratory [SI units: ng/mL×3.47=nmol/L]. Informed written consent was given by the patients’ parents.


The outcome in 188 prepubertal boys after priming with testosterone was analyzed. Only five patients showed adverse side effects (Table 1). The boy who was accidentally primed with 250 mg testosterone did not show any adverse side effect. Thus, the calculated overall adverse side effect rate after priming with testosterone was 2.7% in our cohort.

Table 1:

Serum testosterone levels (ng/mL) in boys with reported adverse side effects after priming with depot testosterone.

Side effectDose, mgTestosteronea
Patient 1Low flow priapism1254.01
Patient 2Low flow priapism1254.31
Patient 3Stuttering priapism+ testicular pain507.97
Patient 4Testicular pain5026.3
Patient 5Testicular pain50Not available
  1. ang/mL×3.47=nmol/L.

Case reports

Patients 1+2

Two boys (twins aged 12 years) developed severe low-flow priapism 2 weeks after the i.m. injection of 125 mg testosterone. When asked, the boys denied any sexual manipulation, e.g. masturbation. But we cannot exclude this fact. In both cases, conservative treatment did not lead to detumescence. Finally, decompression of the cavernous bodies by blood aspiration had to be performed in the Division of Paediatric Urology. After the intervention, therapy with etilefrin hydrochloride for 1 week was initiated. Hematologic and toxicologic reasons for priapism were excluded. The testosterone levels at the time of the GH tests ranged between 4.01 and 4.03 ng/mL. Testosterone levels at the time of the manifestation of the priapism were not measured.

Patient 3

A 10-year-old boy, primed with 50 mg testosterone i.m., suffered from stuttering priapism and testicular pain starting 5 days after the injection. The symptoms were self-limiting within a few days so no further urologic diagnostics or therapy were necessary. The serum testosterone level at the time of the GH test was 7.97 ng/mL.

Patients 4+5

Two boys aged 10 years who had been primed with 50 mg testosterone i.m. reported testicular pain without priapism. The testosterone level of patient 4 was 26.3 ng/mL, the testosterone level of patient 5 was not available.

Serum testosterone levels

Serum testosterone levels of 95 boys (n=87: primed with 50 mg; n=8: primed with 125 mg) without side effects ranged from 0.38 to 46.1 ng/mL (mean±SD: 9.8±7.7, median: 6.2). There was no significant difference in the testosterone levels (mean±SD) between the two doses (50 mg: 9.9±7.8; 125 mg: 10.6±5.5). The testosterone levels in four of the five boys with side effects (missed: n=1) ranged from 4.0 to 26.3 ng/mL and were within the range of the boys without side effects (Table 1). The testosterone level of the boy who was accidentally primed with 250 mg testosterone was 18.2 ng/mL. There was no association between adverse effects and the serum testosterone levels.


The aim of our study was to evaluate the outcome of prepubertal boys primed with a single i.m. testosterone dosage before GH axis testing. The present study shows that there is a small risk of side effects for prepubertal boys. Generally, testosterone therapy is regarded as safe in children particularly when used in boys with hypogonadism. However, it is well known that adverse side effects might occur after high-dose testosterone application, but the reported data are not consistent.

In boys with excessively tall stature, who were treated with high doses of testosterone (500–1000 mg/month) for reduction of final height [6, 7], the most prevalent adverse side effect was acne [8, 9], but aggressive behavior and troublesome erections have also been reported [10].

Priapism is a prolonged and often painful penile erection lasting >4 h. There are three widely accepted types of priapism: (1) low-flow or ischemic priapism when blood gets trapped in the erection chambers, (2) stuttering priapism, recurrent, self-limiting prolonged erections and (3) high-flow or non-ischemic priapism when the blood flow from the penis is prevented usually due to trauma [11]. One of the most feared side effects of testosterone therapy is low-flow priapism which is often associated with devastating complications. In patients with sickle cell disease (SCD), there is a significant concern for these sequelae [12, 13]. However, it has been reported that the risk of priapism was not higher after treatment with a high dose i.m. testosterone undecanoate in SCD patients with hypogonadism [14]. On the contrary, Donaldson et al. [12] described a boy with SCD at the age of 14.7 years who received i.m. testosterone (0.6 mL Sustanon 250®, Organon Laboratories Limited, Hertfordshire, UK) for priming prior to GH testing. Three days after the injection, he presented with a prolonged painful nocturnal erection. Ichioka et al. [15] reported on a low-flow priapism in a patient with Klinefelter syndrome within 12 days after an accidental high dose of 500 mg depot testosterone. Zargooshi et al. [16] reported low-flow priapism in a patient with hypogonadism starting 12 h after the application of 500 mg testosterone. A painful erection was reported in a 15-year-old boy with constitutional delay of growth and puberty (CDGP) after 250 mg depot testosterone [12]. Thus, it was speculated that the appearance of side effects might be related to the high testosterone dosage.

However, there are also case reports in the literature on side effects after low-dose testosterone replacement therapy performed in boys and men with hypogonadism and in boys with CDGP [12, 15, 16, 17, 18]. Arrigo et al. [19] reported a 14-year-old boy who had suffered from high-flow priapism after the 2nd monthly injection of 25 mg depot testosterone. Madrid Garcia et al. [18] found a 14-year-old boy with CDGP with priapism after administration of 100 mg testosterone which required the punction-aspiration of the corpora cavernosa. Shergill et al. [17] reported an 18-year-old patient with Kallmann’s syndrome who developed low-flow priapism 10 days after the first injection of 100 mg testosterone.

We cannot finally evaluate the symptom of testicular pain. Testicular pain has a number of possible causes, e.g. testicular torsion or orchitis but the cause cannot always be identified. Our data show that priapism and testicular pain might also occur in prepubertal boys who received a single testosterone dosage of either 50 mg or 125 mg for priming prior to GH testing. The injected testosterone dose was slightly higher in the two boys with severe priapism with a need for urologic intervention than in the boys with self-limiting stuttering priapism or testicular pain. One could speculate that the adverse effects are due to a sudden exuberant rise of the serum testosterone level. However, the serum testosterone levels in the patients with side effects were in the range of the testosterone levels in the boys without any side effects.


Parents and patients should be informed that the overall side effect rate is low after a single i.m. administration of testosterone for priming before GH testing. However, if side effects such as priapism and/or testicular pain occur, the children should be promptly presented to an urologist.

Corresponding author: Prof. Dr. med. Helmuth G. Dörr, Division of Paediatric Endocrinology, Department of Paediatrics, University Hospital, Friedrich Alexander-Universität Erlangen-Nürnberg, Loschgestr. 15, 91054 Erlangen, Germany, Phone: +49 (0) 9131-853-3732

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


1. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab 2000;85:3990–3.Search in Google Scholar

2. Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, et al. Guidelines for growth hormone and insulin-like growth factor-i treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr 2016;86:361–97.10.1159/000452150Search in Google Scholar PubMed

3. Binder G, Brämswig JH, Kratzsch J, Pfäffle R, Woelfle J. Diagnosis of growth hormone defciency in children (in German). Kinder- und Jugendmedizin 2009;9:461–4.Search in Google Scholar

4. Lazar L, Phillip M. Is sex hormone priming in peripubertal children prior to growth hormone stimulation tests still appropriate? Horm Res Paediatr 2010;73:299–302.10.1159/000284396Search in Google Scholar PubMed

5. Chesover AD, Dattani MT. Evaluation of growth hormone stimulation testing in children. Clin Endocrinol (Oxf) 2016;84:708–14.10.1111/cen.13035Search in Google Scholar PubMed

6. de Waal WJ, Torn M, de Muinck Keizer-Schrama SM, Aarsen RS, Drop SL. Long term sequelae of sex steroid treatment in the management of constitutionally tall stature. Arch Dis Child 1995;73:311–5.10.1136/adc.73.4.311Search in Google Scholar PubMed PubMed Central

7. Drop SL, De Waal WJ, De Muinck Keizer-Schrama SM. Sex steroid treatment of constitutionally tall stature. Endocrine Rev 1998;19:540–58.Search in Google Scholar

8. Brämswig JH, Schellong G, Borger HJ, Breu H. [Testosteron treatment of excessively tall boys (author’s transl)]. Dtsch Med Wochenschr 1981;106:1656–61.10.1055/s-2008-1070573Search in Google Scholar PubMed

9. Traupe H, von Muhlendahl KE, Brämswig J, Happle R. Acne of the fulminans type following testosterone therapy in three excessively tall boys. Arch Dermatol 1988;124:414–7.10.1001/archderm.1988.01670030080027Search in Google Scholar

10. Hannema SE, Savendahl L. The evaluation and management of tall stature. Horm Res Paediatr 2016;85:347–52.10.1159/000443685Search in Google Scholar PubMed

11. Donaldson JF, Rees RW, Steinbrecher HA. Priapism in children: a comprehensive review and clinical guideline. J Pediatr Urol 2014;10:11–24.10.1016/j.jpurol.2013.07.024Search in Google Scholar PubMed

12. Donaldson JF, Davis N, Davies JH, Rees RW, Steinbrecher HA. Priapism in teenage boys following depot testosterone. J Pediatr Endocrinol Metab 2012;25:1173–6.10.1515/jpem-2012-0270Search in Google Scholar PubMed

13. Slayton W, Kedar A, Schatz D. Testosterone induced priapism in two adolescents with sickle cell disease. J Pediatr Endocrinol Metab 1995;8:199–203.10.1515/JPEM.1995.8.3.199Search in Google Scholar PubMed

14. Morrison BF, Reid M, Madden W, Burnett AL. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report. Andrology 2013;1:576–82.10.1111/j.2047-2927.2013.00084.xSearch in Google Scholar

15. Ichioka K, Utsunomiya N, Kohei N, Ueda N, Inoue K, et al. Testosterone-induced priapism in Klinefelter syndrome. Urology 2006;67:622.e17–8.10.1016/j.urology.2005.09.041Search in Google Scholar

16. Zargooshi J. Priapism as a complication of high dose testosterone therapy in a man with hypogonadism. J Urol 2000;163:907.10.1016/S0022-5347(05)67836-6Search in Google Scholar

17. Shergill IS, Pranesh N, Hamid R, Arya M, Anjum I. Testosterone induced priapism in Kallmann’s syndrome. J Urol 2003;169:1089.10.1097/01.ju.0000049199.37765.c9Search in Google Scholar PubMed

18. Madrid Garcia FJ, Diez Hernandez A, Madronero Cuevas C, Rivas Escudero JA, Delgado Gomez M, et al. [Priapism secondary to testosterone administration in the treatment of delayed puberty]. Archivos espanoles de urologia 2001;54:703–5.Search in Google Scholar

19. Arrigo T, Crisafulli G, Salzano G, Zirilli G, De Luca F. High-flow priapism in testosterone-treated boys with constitutional delay of growth and puberty may occur even when very low doses are used. J Endocrinol Invest 2005;28:390–1.10.1007/BF03347210Search in Google Scholar PubMed

Article note:

Presented in part at the 55th Annual Meeting of the ESPE 2016, Paris, France.

Received: 2017-7-17
Accepted: 2017-10-31
Published Online: 2017-12-4
Published in Print: 2018-1-26

©2018 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 6.12.2023 from
Scroll to top button